{
    "clinical_study": {
        "@rank": "57219", 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against\n      cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients\n      with severe immunosuppression.\n\n      The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until\n      recently, both drugs required intravenous administration. An oral form of ganciclovir, if\n      shown to be effective therapy against CMV, would be a more suitable method of administration\n      for prophylaxis."
        }, 
        "brief_title": "The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV", 
        "completion_date": {
            "#text": "August 1995", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections", 
            "Gastrointestinal Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Gastrointestinal Diseases", 
                "Digestive System Diseases", 
                "Retinitis", 
                "Stomach Diseases", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until\n      recently, both drugs required intravenous administration. An oral form of ganciclovir, if\n      shown to be effective therapy against CMV, would be a more suitable method of administration\n      for prophylaxis.\n\n      Patients are randomized in a 2:1 ratio to receive either oral ganciclovir or placebo for a\n      minimum of 12 months. PER AMENDMENT 9/19/94:  Patients who have not reached a study endpoint\n      may choose to continue blinded prophylaxis or discontinue blinded prophylaxis and begin\n      open-label ganciclovir. PER AMENDMENT 5/2/95: After the common closing date (6/3/95)\n      patients who have not met a CMV end point or experienced a serious toxicity that required\n      permanent discontinuation of active oral ganciclovir will be eligible to receive open-label\n      oral ganciclovir through an open-label extension phase of study 023 until 8/31/95."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiretroviral therapy.\n\n          -  Anti-PCP prophylaxis.\n\n          -  Maintenance or prophylaxis therapy for other opportunistic infections besides CMV.\n\n        Patients must have:\n\n          -  Working diagnosis of HIV infection.\n\n          -  CD4 count <= 100 cells/mm3.\n\n          -  Positive CMV serology (IgG) or CMV culture, in the absence of active disease,\n             documented at any time prior to study entry.\n\n          -  Reasonably good health.\n\n          -  Life expectancy of at least 6 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Acute life-threatening illness.\n\n          -  Active lymphoma.\n\n          -  Hypersensitivity to acyclovir.\n\n          -  Lack of willingness or ability, in the opinion of the clinician, to comply with\n             protocol requirements.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Vidarabine.\n\n          -  Amantadine hydrochloride (Symmetrel).\n\n          -  CMV hyperimmune globulin/intravenous immune globulin.\n\n          -  Cytarabine.\n\n          -  Fiacitabine (FIAC) or fialuridine (FIAU).\n\n          -  Foscarnet.\n\n          -  Intravenous ganciclovir.\n\n          -  HPMPC.\n\n          -  Idoxuridine.\n\n          -  Intravenous acyclovir.\n\n          -  Oral acyclovir at > 1 g/day.\n\n          -  Other drugs with potential anti-CMV activity.\n\n        Prior Medication:\n\n        Excluded within 60 days prior to study entry:\n\n          -  Foscarnet.\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Vidarabine.\n\n          -  Amantadine hydrochloride (Symmetrel).\n\n          -  CMV hyperimmune globulin/intravenous immune globulin.\n\n          -  Cytarabine.\n\n          -  Fiacitabine (FIAC) or fialuridine (FIAU).\n\n          -  Ganciclovir.\n\n          -  HPMPC.\n\n          -  Idoxuridine.\n\n          -  Intravenous acyclovir.\n\n          -  Oral acyclovir at > 1 g/day.\n\n          -  Other drugs with potential anti-CMV activity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "850", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001034", 
            "org_study_id": "CPCRA 023", 
            "secondary_id": "11573"
        }, 
        "intervention": {
            "intervention_name": "Ganciclovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ganciclovir"
        }, 
        "keyword": [
            "Retinitis", 
            "Ganciclovir", 
            "Cytomegalovirus Infections", 
            "Administration, Oral", 
            "Acquired Immunodeficiency Syndrome", 
            "Gastrointestinal System"
        ], 
        "lastchanged_date": "September 28, 2013", 
        "link": {
            "description": "Click here for more information about Ganciclovir", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=18"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "Community Consortium of San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80204"
                    }, 
                    "name": "Denver CPCRA / Denver Public Hlth"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19899"
                    }, 
                    "name": "Wilmington Hosp / Med Ctr of Delaware"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20422"
                    }, 
                    "name": "Veterans Administration Med Ctr / Regional AIDS Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "AIDS Research Alliance - Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Comprehensive AIDS Alliance of Detroit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kenilworth", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07033"
                    }, 
                    "name": "Schering - Plough Corp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07103"
                    }, 
                    "name": "North Jersey Community Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10456"
                    }, 
                    "name": "Bronx Lebanon Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11201"
                    }, 
                    "name": "Addiction Research and Treatment Corp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10037"
                    }, 
                    "name": "Harlem AIDS Treatment Group / Harlem Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Clinical Directors Network of Region II"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Portland Veterans Adm Med Ctr / Rsch & Education Grp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Richmond AIDS Consortium"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression", 
        "overall_official": [
            {
                "last_name": "Brosgart C", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Craig C", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "citation": "Brosgart C, Craig C, Louis TA, Hillman D, Costanzo L, Timpone J, Scott J, Nunley F, Stempien MJ. Design and demographics in a multicenter trial of cytomegalovirus (CMV) prophylaxis in advanced HIV disease. Int Conf AIDS. 1994 Aug 7-12;10(2):10 (abstract no 331B)"
            }, 
            {
                "PMID": "9517989", 
                "citation": "Brosgart CL, Louis TA, Hillman DW, Craig CP, Alston B, Fisher E, Abrams DI, Luskin-Hawk RL, Sampson JH, Ward DJ, Thompson MA, Torres RA. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 1998 Feb 12;12(3):269-77."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001034"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "AIDS Research Alliance - Chicago": "41.878 -87.63", 
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Addiction Research and Treatment Corp": "40.653 -73.959", 
        "Bronx Lebanon Hosp Ctr": "40.85 -73.867", 
        "Clinical Directors Network of Region II": "40.714 -74.006", 
        "Community Consortium of San Francisco": "37.775 -122.419", 
        "Comprehensive AIDS Alliance of Detroit": "42.331 -83.046", 
        "Denver CPCRA / Denver Public Hlth": "39.739 -104.985", 
        "Harlem AIDS Treatment Group / Harlem Hosp Ctr": "40.714 -74.006", 
        "Henry Ford Hosp": "42.331 -83.046", 
        "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med": "29.951 -90.072", 
        "North Jersey Community Research Initiative": "40.736 -74.172", 
        "Portland Veterans Adm Med Ctr / Rsch & Education Grp": "45.523 -122.676", 
        "Richmond AIDS Consortium": "37.541 -77.436", 
        "Schering - Plough Corp": "40.676 -74.291", 
        "Veterans Administration Med Ctr / Regional AIDS Program": "38.895 -77.036", 
        "Wilmington Hosp / Med Ctr of Delaware": "39.746 -75.547"
    }
}